How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

800 results for

Lidocaine Patch

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Sweet 16 (papers of the year for NYGH EMU 2017)

Sweet 16 (papers of the year for NYGH EMU 2017) Sweet 16 (papers of the year for NYGH EMU 2017) - First10EM Search Sweet 16 (papers of the year for NYGH EMU 2017) by | Published - Updated At this year’s , I was asked to review the most important emergency medicine papers of the year. These are the 10 papers I decided to talk about. If you have questions or comments, please join the discussion at the bottom of the post. Placebo is as good as (or maybe better than) amiodarone or lidocaine for out (...) of hospital cardiac arrest (the ALPS trial) Kudenchuk PJ et al. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. NEJM 2016. PMID: Methods: Large multicenter, randomized, double blind trial. Included a total of 3026 patients (4653 in the intention to treat analysis) 18 years of age or older with nontraumatic out of hospital cardiac arrest and shock-refractory ventricular fibrillation or pulseless ventricular tachycardia (defined as persistent or recurrent VF or pulseless VT after one

2017 First10EM

282. Why this anesthesiologist says “no” to fentanyl

in an era of cost containment in healthcare. When I started my anesthesia residency, we assumed that since fentanyl’s analgesic and euphoric effects were so brief, short-term exposure to the drug wouldn’t increase a patient’s risk of long-term narcotic abuse. For the first few years, fentanyl was kept in unsecured medication carts in the operating rooms along with Benadryl, lidocaine, and other commonly used medications. But anesthesiology departments quickly learned that fentanyl did indeed have high (...) abuse potential. Its pleasurable “high” and rapid onset proved irresistible to some people, and deaths from overdose occurred all too often among medical personnel. Now, we track every microgram of fentanyl used or discarded during surgery. Fentanyl stayed quietly under the radar for decades as an IV drug useful primarily in anesthesiology practice. But it began to see more use in the treatment of chronic pain — as transdermal patches, or “ ” for absorption by mouth. And with its increased

2017 KevinMD blog

283. Neuropathic low back pain in clinical practice. Full Text available with Trip Pro

and NSAIDs, although widely used for LBP, are unlikely to ameliorate the neuropathic component and data on the use of NP medications such as antidepressants and gabapentin/pregabalin are limited. While there is an unmet need for improved treatment options, recent data have shown tapentadol to have efficacy in the neuropathic component of LBP, and studies suggest that the capsaicin 8% patch and lidocaine 5% medicated plaster, topical analgesics available for the treatment of peripheral NP, may (...) and topical analgesics - such as the capsaicin 8% patch and the lidocaine 5% medicated plaster - may be effective options for the treatment of neuropathic low back pain in defined patient groups.© 2016 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation - EFIC®.

2016 European Journal of Pain

284. Buprenorphine Transdermal System (Butrans)

in response to a report of severe, late onset application site reactions associated with use of Norspan/Butrans in the United Kingdom. The safety analysis dated 12-Feb-2010 identified 1,335 cases (through 27-Aug-2009) involving 2,637 skin associated adverse events in patients treated with buprenorphine in the international drug safety database. According to the applicant the majority of the cases lacked latency data but some which were severe occurred weeks to months after initiating patch. Many (...) of the cases were consistent with allergic contact dermatitis. The applicant also identified four articles describing a total of nine case reports of allergic contact dermatitis, confirmed by patch testing. Of the 1335 cases, 183 cases contained latency information. Approximately 45% of the cases with latency data had skin reactions within the first 10 days and 36% within the first day. However, 55% of patch site reactions occurred after 10 days and approximately 24% occurred after 100 days

2010 FDA - Drug Approval Package

285. Herpes Zoster. (Abstract)

lidocaine patch, gabapentin, pregabalin, tricyclic antidepressants, or opiates can reduce pain burden. The live attenuated zoster vaccine is effective in reducing pain burden and preventing herpes zoster and PHN in older adults.Copyright © 2016 Elsevier Inc. All rights reserved.

2016 Clinics in Geriatric Medicine

286. A Novel Na<sub>V</sub>1.5 Voltage Sensor Mutation Associated with Severe Atrial and Ventricular Arrhythmias. Full Text available with Trip Pro

A Novel NaV1.5 Voltage Sensor Mutation Associated with Severe Atrial and Ventricular Arrhythmias. Inherited autosomal dominant mutations in cardiac sodium channels (NaV1.5) cause various arrhythmias, such as long QT syndrome and Brugada syndrome. Although dozens of mutations throughout the protein have been reported, there are few reported mutations within a voltage sensor S4 transmembrane segment and few that are homozygous. Here we report analysis of a novel lidocaine-sensitive (...) recessive mutation, p.R1309H, in the NaV1.5 DIII/S4 voltage sensor in a patient with a complex arrhythmia syndrome.We expressed the wild type or mutant NaV1.5 heterologously for analysis with the patch-clamp and voltage clamp fluorometry (VCF) techniques. p.R1309H depolarized the voltage-dependence of activation, hyperpolarized the voltage-dependence of inactivation, and slowed recovery from inactivation, thereby reducing the channel availability at physiologic membrane potentials. Additionally

2016 Journal of Molecular and Cellular Cardiology

287. Accidental Dural Puncture Management: 10-Year Experience at an Academic Tertiary Care Center. (Abstract)

or had a spinal catheter (with or without the administration of intrathecal saline). We compared the incidence of headache and the need for blood patch between these groups. We also assessed complications when a standard lidocaine epidural test dose was administered intrathecally and compared this with complications when a solution normally used for labor combined spinal epidurals was administered.There was no difference in the incidence of postdural puncture headache between the resited epidural (...) of blood patches between normal body mass index patients and morbidly obese patients, 55.2% versus 25.0% (OR, 3.7; 95% CI, 1.2-11.2; P = 0.02). Complications (hypotension prompting pressors, high spinal, and emergency cesarean delivery because of nonreassuring fetal status) occurred more frequently when a lidocaine test dose was immediately administered after ADP versus administering a labor combined spinal epidural solution.Insertion of spinal catheters after ADP and administration of intrathecal

2016 Regional Anesthesia and Pain Medicine

288. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology Full Text available with Trip Pro

specific medications to treat pain. Current guidelines recommend treatment of postherpetic neuralgia in a hierarchical manner, with calcium channel α2-δ ligands (gabapentin and pregabalin), tricyclic antidepressants (amitriptyline, nortriptyline, or desipramine), or topical lidocaine patches as first-line drugs. The safety and tolerability of pharmacologic therapies for pain are important issues to consider as postherpetic neuralgia affects primarily an older population. Patients should be educated

2016 Journal of multidisciplinary healthcare

289. Development of a Rapid Throughput Assay for Identification of hNav1.7 Antagonist Using Unique Efficacious Sodium Channel Agonist, Antillatoxin Full Text available with Trip Pro

potential change. The ATX response was completely inhibited by tetrodotoxin suggesting that the ATX response was solely derived from hNav1.7 activation, which was consistent with the results where ATX produced a negligible response in null HEK-293 cells. Six VGSC antagonists including lidocaine, lamotrigine, phenytoin, carbamazepine, riluzole, and 2-amino-6-trifluoromethylthiobenzothiazole all concentration-dependently inhibited ATX response with IC50 values comparable to that reported from patch-clamp

2016 Marine drugs

290. Myometrial relaxation of mice via expression of two pore domain acid sensitive K+ (TASK-2) channels Full Text available with Trip Pro

. Isometric contraction measurements and patch clamp technique were used to verify TASK conductance in murine myometrium. Western blot and immunehistochemical study under confocal microscopy were used to investigate molecular identity of TASK channel. In this study, we showed that TEA and 4-AP insensitive non-inactivating outward K(+) current (NIOK) may be responsible for the quiescence of murine pregnant longitudinal myometrium. The characteristics of NIOK coincided with two-pore domain acid-sensing K (...) (+) channels (TASK-2). NIOK in the presence of K(+) channel blockers was inhibited further by TASK inhibitors such as quinidine, bupivacaine, lidocaine, and extracellular acidosis. Furthermore, oxytocin and estrogen inhibited NIOK in pregnant myometrium. When compared to non-pregnant myometrium, pregnant myometrium showed stronger inhibition of NIOK by quinidine and increased immunohistochemical expression of TASK-2. Finally, TASK-2 inhibitors induced strong myometrial contraction even in the presence of L

2016 The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

291. The Interest of the Xylocaine® and Ketamine on the Management of Acute and Chronic Ain After Colectomy by Laparoscopy

opioids Patients treated with lidocaine patch Psychic Disorder Additive Conduct vis-à-vis alcohol or mind-altering substances Pregnant or breastfeeding women Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02969733 Locations Layout table for location (...) : September 12, 2017 Last Verified: September 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by University Hospital, Lille: postoperative analgesia PainMatcher Additional relevant MeSH terms: Layout table for MeSH terms Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Signs and Symptoms Ketamine Lidocaine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs

2016 Clinical Trials

292. Ambroxol in Disease Modification in Parkinson Disease

with a Failure Rate of < 1%: Oral contraceptive, either combined or progestogen alone; Injectable progestogen; Implants of levonorgestrel; Estrogenic vaginal ring; Percutaneous contraceptive patches; Intrauterine device (IUD) or intrauterine system (IUS) that meets the <1% failure rate as stated in the product label; Please note: All male and female participants of child bearing potential must agree with their partners to use double-barrier birth control or abstinence while participating in the study (...) their participation; History of known rare hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption; Evidence or history of hypersensitivity to lidocaine or its derivatives; History of drug abuse or alcoholism in the opinion of the Investigator that would preclude participation in the study; Donation of blood (one unit or 350 ml) within three months prior to receiving the first dose of the study drug; Pregnant or breastfeeding; All participants of child bearing

2016 Clinical Trials

293. Phase I Pharmacokinetic Study of RX0041-2

and ≤ 32 at the screening visit. Females (if of child-bearing potential and sexually active) and males (if sexually active with a partner of child-bearing potential) who agree to use a medically acceptable and effective birth control method from the first dose and for 8 days following administration of study drug. Medically acceptable methods of contraception that may be used by the participant and/or his/her partner include abstinence, birth control pills or patches, diaphragm, intrauterine device (...) , chloroprocaine, dibucaine, or benzocaine Amide based anesthetic allergies are NOT exclusionary. Amide based anesthetics are: Lidocaine, mepivicaine, bupivicaine, levobupivicaine, ropivicaine, etidocaine, prilocaine, and articaine. The use of amphetamines, methylphenidate or other stimulant prescription and nonprescription products such as pseudoephedrine, bronchial inhalers containing sympathomimetics (epinephrine or other beta-receptor agonist) or herbal products in the 7 days prior to screening or has

2016 Clinical Trials

294. Efficacy of Iontophoresis-assisted AFL-PDT in Actinic Keratosis

Study Details Study Description Go to Brief Summary: Iontophoresis is a transdermal drug-delivery technique that enhances the transport of ionic species across membranes and may have significant benefit for the treatment of actinic keratosis (AK) by ablative fractional laser-primed photodynamic therapy (AFL-PDT). Condition or disease Intervention/treatment Phase Actinic Keratosis Drug: lidocaine/prilocaine (5%) application Device: 2940-nm Er:YAG AFL pretreatment Drug: MAL application Device (...) Date : June 2014 Actual Primary Completion Date : December 2015 Actual Study Completion Date : December 2015 Resource links provided by the National Library of Medicine resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Group A (short-time iontophoresis group) Group A was treated with iontophoresis-assisted AFL-PDT with a short incubation time (2 h) Drug: lidocaine/prilocaine (5%) application For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra

2016 Clinical Trials

295. TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest

: --Skin phototype of Fitzpatrick Type I-IV For FEMALE SUBJECT OF CHILDBEARING POTENTIAL, must have had a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study [i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings (...) . A subject with an active bacterial, fungal, or viral infection in the treatment area. A subject with known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-aminobenzoic acid), or other local anesthetics of the amide or ester family sedation medication. A subject with known allergy or sensitivity to propylene glycol or any other ingredient of topical TR-987 or placebo. A subject receiving any topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or E

2016 Clinical Trials

296. A Study Investigating the Effects of Niagenâ„¢ in Healthy Adults.

, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Non-hormonal intrauterine devices Vasectomy of partner Healthy as determined by laboratory results, medical history, and physical exam Agrees to comply with study procedure Agrees to maintain current level of physical activity throughout the study and avoid exercising on the day of study visits 3 to 7 (prior (...) or sensitivity to lidocaine Bleeding disorder Serum creatinine ≥ 130µmol/L for males and ≥ 125µmol/L for female Individuals who are cognitively impaired and/or who are unable to give informed consent Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or which may pose significant risk to the subjects Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2016 Clinical Trials

297. Comparison of the Efficacy of the Ultrasound With Fluoroscopy in Guidance of Lumbar Sympathetic Block

Block (LSB) The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position. Device: Ultrasound for Lumbar Sympathetic Block (LSB) Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra (...) intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle. Procedure: Temperature measurement for Lumbar Sympathetic Block (LSB) Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min. Procedure: Postprocedure care for LSB Adverse events

2016 Clinical Trials

298. Multicenter Double-Blind Randomized Split-Face Study to Evaluate Revanesse® Ultra vs Restylane® for Correction of NLF

and of childbearing potential, a negative urine pregnancy test and agree to use adequate contraception. Female subjects of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 2 years) must have a negative urine pregnancy test and must be willing to use a medically accepted method of contraception during the study. The following are considered acceptable methods of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive (...) or hypertrophic scars. Any infection or wound on the face. Allergic history including anaphylaxis or multiple severe allergies to natural rubber latex or lidocaine. Aspirin or nonsteroidal anti-inflammatory drugs within 1 week (7 days) prior to treatment. Concomitant anticoagulant therapy, antiplatelet therapy, or history of bleeding disorders or connective tissue disorders. Over-the-counter (OTC) wrinkle products or prescription wrinkle treatments within 4 weeks (28 days) prior to treatment and throughout

2016 Clinical Trials

299. Study to Evaluate Safety and Efficacy of Revanesse® Ultra + vs Revanesse® Ultra for Correction of NLF

18, 2018 Sponsor: Prollenium Medical Technologies Inc. Information provided by (Responsible Party): Prollenium Medical Technologies Inc. Study Details Study Description Go to Brief Summary: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra + (with Lidocaine) versus Revanesse® Ultra for the Correction of Nasolabial Folds to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine, hereafter referred (...) to as Revanesse Ultra +) to Revanesse Ultra for subjects undergoing correction of nasolabial folds (NLFs) Condition or disease Intervention/treatment Phase Nasolabial Fold Correction Device: Revanesse Ultra+ (with lidocaine) Device: Revanesse Ultra Not Applicable Detailed Description: This is a randomized, multicenter, double-blind, split-face study in subjects seeking nasolabial fold correction. Subjects will be treated with Revanesse Ultra + in the NLF on one side of the face and Revanesse Ultra in the NLF

2016 Clinical Trials

300. Standard TDS Irritation Study: Trained Skin Grader vs. Digital Imaging

Lidocaine 5%; RLD Not Applicable Detailed Description: Subjects will be screened prior to dosing to ensure subjects meet all inclusion exclusion criteria. The test materials will be tested simultaneously. Skin sites on the paraspinal region will be utilized for application. The test sites will be randomized among the individual subjects according to their assigned identification number. All patches will be applied and removed by the laboratory staff. Due to safety concerns, it is not recommended (...) to simultaneously apply two whole, active, Lidocaine Patch 5% patches on the same subject during the 21-day period. The optimum design of this study will depend on the design of the test product patch. Since the RLD has a matrix design that can be safely cut, one-fourth of the patch can be used for these studies. If the test product patch also has a design that can be cut to a smaller size, it should also be cut in one-fourth and one-fourth of the test product patch applied simultaneously with one-fourth

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>